News
Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...
SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...
One in five Irish people said they would not take a traditional vaccine, a worldwide research project found. A further one in ...
South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...
Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...
Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...
12d
Live Science on MSNWhat are mRNA vaccines, and how do they work?RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The Slovak government halted purchases of COVID-19 vaccines on Wednesday pending a review of their safety by the Slovak ...
SK Bioscience announced Wednesday that it has secured a definitive legal victory in its patent invalidation suit against Moderna, successfully challenging the biotech giant’s Korean patent related to ...
1d
Yonhap News Agency on MSNSK bioscience wins patent case against Moderna in S. KoreaSEOUL, April 23 (Yonhap) -- SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results